Maridea Wealth Management LLC Takes $496,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Maridea Wealth Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,373 shares of the biopharmaceutical company's stock, valued at approximately $496,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Southland Equity Partners LLC grew its position in shares of Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock worth $289,000 after purchasing an additional 110 shares in the last quarter. Berkshire Bank boosted its stake in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 111 shares during the period. CFO4Life Group LLC grew its holdings in Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after buying an additional 112 shares in the last quarter. Howe & Rusling Inc. raised its position in shares of Gilead Sciences by 2.5% during the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock valued at $435,000 after buying an additional 115 shares during the last quarter. Finally, GHP Investment Advisors Inc. lifted its holdings in shares of Gilead Sciences by 1.1% in the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company's stock worth $1,049,000 after buying an additional 122 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Remove Ads

Gilead Sciences Stock Down 0.7 %

NASDAQ GILD traded down $0.77 on Tuesday, reaching $111.28. 6,218,323 shares of the stock traded hands, compared to its average volume of 7,287,868. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a fifty day moving average price of $105.88 and a 200-day moving average price of $95.20. The company has a market cap of $138.58 billion, a price-to-earnings ratio of 300.76, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is currently 854.05%.

Analysts Set New Price Targets

A number of brokerages have issued reports on GILD. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Wells Fargo & Company lifted their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, The Goldman Sachs Group increased their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $105.12.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.